Compare BANF & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANF | TMDX |
|---|---|---|
| Founded | 1984 | 1998 |
| Country | United States | United States |
| Employees | 2135 | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.6B |
| IPO Year | N/A | 2019 |
| Metric | BANF | TMDX |
|---|---|---|
| Price | $116.49 | $135.11 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $129.50 | ★ $152.33 |
| AVG Volume (30 Days) | 77.0K | ★ 728.7K |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | N/A | ★ 4.87 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $6.10 | $21.96 |
| Revenue Next Year | $3.92 | $17.62 |
| P/E Ratio | ★ $16.38 | $27.07 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $97.02 | $62.07 |
| 52 Week High | $138.15 | $156.00 |
| Indicator | BANF | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 50.41 |
| Support Level | $106.33 | $122.59 |
| Resistance Level | $124.87 | $142.44 |
| Average True Range (ATR) | 3.35 | 6.67 |
| MACD | -0.42 | 0.04 |
| Stochastic Oscillator | 50.72 | 41.88 |
BancFirst Corp is engaged in providing banking services. The company's business unit includes BancFirst metropolitan banks, BancFirst community banks, Pegasus Bank, Worthington, other financial services and executive, operations and support. BancFirst metropolitan banks, BancFirst community banks, Pegasus and Worthington offer traditional banking products such as commercial and retail lending and a full line of deposit accounts. Other financial services are specialty product business units including guaranteed small business lending, residential mortgage lending, trust services, securities brokerage, electronic banking, and insurance.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.